Ordaōs Bio is pioneering the development of mini-proteins, specifically their miniPRO™ class, which are designed to offer the therapeutic benefits of traditional antibodies while being significantly smaller, more stable, and easier to manufacture. These mini-proteins, typically 20 times smaller than conventional monoclonal antibodies, are engineered to penetrate disease microenvironments effectively, thereby enhancing treatment efficacy. The company employs a unique approach that combines generative AI with a multitask meta-learning Design Engine, allowing for the rapid creation and optimization of these mini-proteins based on specific target product profiles. This innovative process not only accelerates drug development timelines but also aims to reduce patient suffering by addressing high unmet medical needs, particularly in oncology.

The Ordaōs Design Engine plays a crucial role in this process, utilizing continuous learning loops and extensive datasets to generate and evaluate billions of protein sequences and structures. This machine-driven approach enables the design of miniPRO™ proteins that are tailored to meet precise therapeutic criteria, optimizing properties such as binding specificity, stability, and immunogenicity. By focusing on difficult-to-drug targets and leveraging partnerships with other biotech firms, Ordaōs aims to redefine the drug discovery landscape, shifting from traditional discovery methods to a more efficient design-centric model. This strategy not only enhances the probability of clinical success but also positions Ordaōs as a leader in the emerging field of AI-driven drug design.

United States

Ordaos is a human-enabled, machine-driven drug design company that creates novel and customized mini-proteins. Their mission is to help biopharma partners deliver life-saving treatments by creating bespoke mini-proteins to aid drug hunters.

Ordaos Bio

Company Details